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Abstract
Background: Human Cytomegalovirus (HCMV) has acquired through evolution a number of
genes to try to evade immune recognition of the virus-infected cell. Many of these mechanisms act
to inhibit the MHC class I antigen presentation pathway, but any virus-infected cell which has down-
regulated cell surface expression of MHC class I proteins, to avoid CTL attack, would be expected
to become susceptible to lysis by Natural Killer cells. Surprisingly, however, HCMV infected
fibroblasts were found to be resistant to NK cell mediated cytotoxicity. Expression of the UL16
glycoprotein could represent one mechanism to help the virus to escape from NK cell attack, as it
has been shown to bind, in vitro, some of the ligands for NKG2D, the NK cell activating receptor.
Here, we explored the role of UL16, in the context of a viral infection, by comparing the
susceptibility to NK lysis of cells infected with HCMV and cells infected with a UL16 deletion
mutant of this virus.
Results: Cells infected with the UL16 knockout virus were killed at substantially higher levels than
cells infected with the wild-type virus. This increased killing could be correlated with a UL16-
dependent reduction in surface expression of ligands for the NK cell activating receptor NKG2D.
Conclusions: Expression of the UL16 glycoprotein was associated with protection of HCMV-
infected cells from NK cell attack. This observation could be correlated with the downregulation
of cell surface expression of NKG2D ligands. These data represent a first step towards
understanding the mechanism(s) of action of the UL16 protein.
Background
Cytomegaloviruses (CMVs) are members of the β sub-
group of the Herpesvirus family. Cytomegalovirus infec-
tion can be associated with severe, even fatal disease, but
in the immunocompetent host, primary infection with
CMV is normally controlled by the immune system. This
immune control does not result in complete elimination
of the virus. Instead, the virus persists for the lifetime of
the host with occasional episodes of virus reactivation and
shedding. One aspect of CMV biology that almost certain-
ly contributes to this state of permanent cohabitation is
that CMVs have acquired during their evolution an exten-
sive repertoire of gene products that can function to mod-
ulate immune recognition of the virus and virus-infected
cell. Human cytomegalovirus (HCMV), for example, en-
codes genes whose protein products are able to modulate
or inhibit the action of virtually all the arms of the antivi-
ral immune response, ie. interference with the presenta-
tion of viral antigens to CTLs, manipulation of cytokine
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plement response (reviewed in [1,2]).
The MHC class I restricted antigen presentation pathway
is a particular target for HCMV immune subversion strat-
egies, presumably because MHC class I restricted CD8+
cytotoxic T lymphocytes are critical effectors in the host
defence against CMV infection [3–5]. However, other
things being equal, a decrease in cell surface expression of
MHC class I molecules should render the virus-infected
cell susceptible to attack by Natural Killer cells; the "miss-
ing-self" hypothesis [6]. It is thus not surprising that
HCMV has evolved strategies for escaping and/or reducing
NK cell immune surveillance.
To date, three potential viral immune subversion mecha-
nisms have been suggested to be employed by HCMV di-
rected at NK cells. Two of these involve the induction of
expression of decoy ligands able to bind NK cell inhibito-
ry receptors. The first of these ligands, the virus-encoded
MHC class I homologue UL18 can interact directly with
the ILT2 (CD85j) inhibitory receptor [7,8]. The second in-
volves an indirect mechanism, as a peptide from the
HCMV UL40 protein is able to bind to the non-classical
class I molecule HLA-E promoting its surface expression.
The interaction of this MHC complex with the CD94/
NKG2A heterodimer could inhibit NK cells [9,10]. The
third proposed mechanism by which HCMV could evade
NK cell attack depends on the ability of the UL16 glyco-
protein to bind ligands of the NK cell activating receptor
NKG2D [11]. Indeed, soluble recombinant UL16 protein
has been shown to compete with NKG2D for binding to
its ligands and so inhibit NK cell activation.
However, the significance of these potential immune eva-
sion strategies is not clear. Only a subset of NK cells ex-
press ILT2; moreover, antibody blocking of inhibitory
receptors such as KIR, CD94/NKG2A or ILT2 had no effect
on NK lysis of HCMV infected fibroblasts [12,13]. Further,
there are a number of cases in which the results obtained
in experiments with viral proteins expressed in isolation
are not consistent with those derived from experiments
studying the role of these proteins during virus infection.
For example, UL18 expression did not protect HCMV-in-
fected cells from NK cell attack [12]. Experiments testing
for UL40-mediated protection from NK cell attack re-
vealed that cells over-expressing HLA-E loaded with UL40
leader sequence peptide were protected from NK lysis
[9,10] and that this effect required a threshold level of
HLA-E [14]; on the other hand, in a viral infection context,
NK cytotoxicity protection mediated by UL40 [15] could
not be reproduced by other researchers [16]. It is therefore
critically important to study the role of potential immu-
nomodulatory viral proteins in the context of the virus in-
fection to establish the degree of their contribution, if any,
to immune subversion.
Thus, to evaluate the function of UL16, if any, during
HCMV infection, we performed cytotoxicity assays to
compare the susceptibility to NK lysis of cells infected
with HCMV, strain AD169, and cells infected with a UL16
deletion mutant of this virus (∆UL16) [17]. Cells infected
with the virus lacking UL16 expression were markedly
more susceptible to NK lysis than cells infected with wild
type virus. This difference correlated with the observation
that cells infected with the HCMV UL16 knockout ex-
pressed ligands for NKG2D that were not expressed at the
surface of cells infected with a virus with an intact copy of
the UL16 gene. These data demonstrate a direct role for
UL16 in modulating the susceptibility of HCMV infected
cells to lysis by NK cells.
Results and Discussion
Expression of the UL16 glycoprotein protects HCMV in-
fected fibroblasts from NK cell attack
It has previously been reported that infection of fibrob-
lasts with HCMV results in protection from NK cell lysis
and that this phenomenon does not depend on ligation of
NK cell inhibitory receptors [13]. However, NK cell activa-
tion depends on a balance of both activating and inhibi-
tory receptors [18,19]. Thus the molecular basis of
HCMV-induced protection from NK cell attack could be
due to viral modulation of target cell ligands for NK cell
activating receptors. The HCMV UL16 glycoprotein has
been shown to bind at least some of the ligands for the NK
cell activating receptor NKG2D [11], but its function, if
any, during viral infection had not been studied. In order
to study whether UL16 plays a role in evading the innate
immune system, NK cell recognition of target cells infect-
ed with either HCMV (strain AD169) or a UL16-knockout
mutant (∆UL16) [17] of AD169 was compared. Cytotox-
icity assays were performed using as effector cells NK cell
lines from multiple healthy donors and as target cells two
lines of human fibroblasts, HFFF2 and Hs27. The result of
one representative experiment is shown in Figure 1. This
experiment showed that cells infected with the virus lack-
ing UL16 gene were killed more efficiently than cells in-
fected with the unmodified AD169 virus, and that
expression of the UL16 glycoprotein resulted in a marked
decrease of the susceptibility of HCMV infected fibrob-
lasts to NK cell attack. The majority of the experiments
were done 36–48 hrs after infection with HCMV, since sig-
nificant levels of UL16 are first detected at this time [17].
However UL16-dependent HCMV-induced protection
from NK cell lysis could also be demonstrated 72 hours
post-infection (data not shown). In brief, specific inactiva-
tion of the UL16 gene led to a loss of resistance of the in-
fected target to NK cell mediated destruction, implying
that expression of the UL16 glycoprotein constitutes aPage 2 of 11
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evade recognition by NK cells.
To explore this phenomenon in more detail, fibroblasts
infected with either AD169 or ∆UL16 were tested in cyto-
toxicity assays for recognition by a panel of NK cell clones.
Representative data from these experiments are summa-
rised in Table 1. The main observation from this analysis
is that UL16 plays an important role in HCMV evasion
from NK cell attack, since in almost every case, ∆UL16 in-
fected cells were much more susceptible to NK cell lysis
than AD169 infected targets. However, these experiments
also provide evidence that, for a minority of NK clones,
other non-UL16-dependent mechanisms that protect the
virus-infected cell from NK lysis can be detected. For ex-
ample, two (out of 15) NK clones (A5 and B6), failed to
kill both AD169 and ∆UL16 infected cells. This behaviour
could depend on the differential expression of a certain
ligand in the target cell, as clone A5 shows different pat-
terns of cytotoxicity with the two targets shown. This hy-
pothesis is entirely consistent with the known
heterogeneity and redundancy of receptor expression ob-
served in NK cell populations. The mechanisms used by
these clones to stop killing of the infected cell could be de-
pendent on the expression of the UL18 and/or UL40 gene
products [8–10,20], although others have either failed to
show an inhibitory effect of these proteins on NK cell rec-
ognition [12–14,16] or have demonstrated an effect only
Figure 1
UL16 protects HCMV infected fibroblasts from NK cell cytotoxicity. Hs27 fibroblasts were mock infected or infected 
with either the laboratory strain of CMV, AD169, or with the same strain of virus lacking UL16, ∆UL16. 48 hours after infec-
tion, these cells were used as targets in cytotoxicity assays (see methods) at the E:T ratios indicated. The percentage of specific 
lysis is depicted. This result is representative of six experiments using in each one, as targets, the two lines of human fibroblasts 
HFFF2 and Hs27. In the different experiments NK cell lines from different donors were used as effectors. Diamonds - unin-
fected cells, squares - HCMV infected cells, triangles - ∆UL16 infected cells.
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there may exist other, as yet undefined viral proteins that
can confer a measure of protection from NK cell lysis. In
any case, the effects due to the mechanisms not depend-
ent on UL16 were seen with only a minority of clones.
Other clones killed mock-infected cells only slightly more
than ∆UL16 infected targets (two clones with the pattern
of D6), as if the NK cell was ignoring that the target was
infected by a virus. This implies that, in this particular
case, a receptor-ligand interaction that would usually lead
to strong activation of the NK clone is now missing. Inter-
estingly, in a few cases HCMV infection did not lead to
protection, but rather appeared to stimulate of NK cell cy-
totoxicity, although again removal of the UL16 gene from
the virus enhanced recognition of the virus-infected cell
by that clone (clones F10 and A8). This could represent
the action of an activating receptor-ligand interaction. An
alternative, not exclusive, explanation for the behaviour
of these clones could be that, a negative signal generated
when the NK cell encountered the non infected fibroblast,
such as a KIR-mediated protection, could be lost in the vi-
rus-infected cell. The latter explanation is plausible in the
case of clones A8, F10 and D9, which behaved following
the cytotoxicity pattern expected from the KIR phenotype
determined from flow cytometry and redirected lysis ex-
periments (data not shown).
In summary, the analysis of recognition of HCMV infected
cells by NK lines and clones clearly shows that expression
of the UL16 gene product results in a reduced susceptibil-
ity of the HCMV infected cell to NK attack. Also, although
this mechanism of protection seems to dominantly affect
the majority of the NK clones, it is used in combination
with others within the virus-infected cell, presumably to
allow the virus to escape from a larger population of NK
cells.
Expression of UL16 affects expression of NKG2D ligands 
at the surface of the HCMV infected cell
Having defined that UL16 expression was associated with
protection of the infected cell from NK cell attack, the ob-
vious next step was to study the mechanism by which this
effect was achieved. Soluble UL16 protein has been
shown to bind, in vitro, the MHC class I related molecules
MICB and ULBPs 1 and 2, also ligands of the NK cell acti-
vating receptor NKG2D. In the same study, soluble UL16
was found to be able to compete with soluble NKG2D for
binding to MICB and ULBPs expressed in the surface of
transfected cells [11]. The simplest hypothesis to explain
the data from the killing assays described above was there-
fore that the UL16 glycoprotein was interfering with the
interaction of the NKG2D receptor with its ligands, thus
blocking NK cell activation.
To test this hypothesis, uninfected fibroblasts as well as fi-
broblasts infected with AD169 or ∆UL16 were stained
with an NKG2D-Ig fusion protein and analysed by flow
cytometry. As controls, the various target cells were also
stained with antibodies to LFA-3 and HLA class I, since in-
fection with HCMV has been shown to induce changes in
cell surface expression of molecules such as LFA-3 [21]
and down-regulation of HLA class I molecule expression
[12] and these changes could contribute to the different
susceptibility to NK lysis of cells infected with different vi-
ruses. The results of these experiments are shown in Fig-
ures 2 and 3.
These data confirm that HCMV infection leads to an in-
crease in cell surface expression of LFA-3 and a decrease in
expression of HLA class I molecules. However, the AD169
and ∆UL16 viruses behaved identically with regard to
alterations in surface expression of these molecules, either
at 2 days (as shown in Figure 2), or at 3 days (not shown),
post-infection. On the other hand, differences in cell sur-
face expression of ligands for the NKG2D receptor could
Table 1: Summary of cytotoxicity patterns of NK clones against HCMV infected human fibroblasts. Numbers express the percentage 
of specific lysis at an E:T ratio of 6:1
Hs27 HFFF2
Representative 
clone
#of clones Uninf. AD169 ∆UL16 Uninf. AD169 ∆UL16
C6 8 18 7 32 13 5 21
A5 1 15 7 25 23 4 5
B6 1 19 4 6 13 4 6
D6 2 19 6 18 26 5 22
F10 1 10 19 32 4 12 21
A8 1 2 15 28 18 8 27
D9 1 6 4 19 6 4 23Page 4 of 11
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LFA-3 and MHC staining in cells infected by CMV wild type and CMV lacking UL16. Hs27 fibroblasts were either 
mock-infected (filled histograms) or infected with the laboratory strain of CMV AD169 (dotted line) and with the same strain 
of virus lacking UL16, ∆UL16 (solid line). Cells were stained for LFA-3 (A) and for MHC class I (B) and analysed on flow cytom-
etry. LFA-3 was up-regulated in CMV infected cells to the same level, whether UL16 was present or not, compared to mock 
infected cells. At the same time, MHC class I became down-regulated in both CMV wild type and ∆UL16CMV infected cells in 
a comparable manner. Data are representative of several experiments and results obtained using both human fibroblast cell 
lines Hs27 and HFFF2 were comparable.
A. LFA-3
B. MHC Class IPage 5 of 11
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The presence of UL16 affects the surface expression of an NKG2D ligand in the context of CMV infection. 
HFFF2 fibroblasts were either mock infected (A) or infected with the laboratory strain of CMV AD169 (B) and with the knock 
out virus lacking UL16 gene, ∆UL16 (C). Cells were stained using NKG2D-Ig protein (solid line) or control human IgG1 (filled 
histograms) and analysed using flow cytometry. Surface expression of NKG2D ligands was much reduced in the CMV infected 
cells and recovered in the absence of UL16. Data are representative of several experiments and results obtained using both 
human fibroblast cell lines Hs27 and HFFF2 were comparable.
A. Mock-infected
B. CMV (AD169) infected
C. CMV (∆UL16) infectedPage 6 of 11
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∆UL16 viruses. In our experiments, both lines of fibrob-
lasts, HFFF2 and Hs27, expressed a ligand(s) for NKG2D,
as previously reported [22]. Strikingly, staining with
NKG2D-Ig was maintained in cells infected with ∆UL16
but was much reduced when the fibroblasts were infected
with the wild type virus (Figure 3). This evidence is con-
sistent with the hypothesis that UL16 interferes with
NKG2D-mediated NK cell activation by sequestering, in-
ternalising or covering a ligand, or ligands, of NKG2D.
The FACS experiments imply that the interaction of the
NKG2D receptor with its ligands is a major signal driving
the activation of NK cell cytotoxicity against HCMV infect-
ed cells. However, it is also apparent that it is not the only
signal influencing the behaviour of the effector. Infection
with both HCMV and ∆UL16 led to a decreased expres-
sion of MHC class I proteins and an increased expression
of LFA-3 molecules (compared to uninfected cells), both
changes expected to conduct to an increased susceptibility
to NK lysis. In addition, infection with wild-type HCMV
also produced a marked reduction in NKG2D ligand ex-
pression, and the net effect of these changes was protec-
tion from lysis. In contrast, ∆UL16 infected cells were
much more susceptible to lysis by NK cells than uninfect-
ed cells, but expressed roughly comparable levels of
NKG2D ligands. The difference in killing in these cases is
presumably influenced by the changes in MHC and LFA-3
expression. These data emphasise once again that NK cell
activation depends on a delicate balance of positive and
negative signals produced by the engagement of numer-
ous activating and inhibitory receptors with their ligands
and that it is changes in the balance of these signals which
determine the behaviour of the NK cell [18,19].
We have not observed any evidence of upregulation of
MICA and MICB on HCMV infection described by Groh et
al [23]. We have no simple explanation for this discrepan-
cy, but suggest that it probably reflects some differences in
the strains of AD169 used in the different sets of experi-
ments. Groh et al used AD169 from the ATCC, whereas in
our experiments we used a separately maintained "UK"
AD169 strain as this was the parental strain used in the
process of construction of the UL16 knockout virus and is
the sequenced isolate of HCMV [24]. Virus variation on
passage is a well recognised phenomenon and in this spe-
cific instance there is independent evidence documenting
significant differences between the AD169varATCC and
AD169varUK viruses [25].
UL16 is necessary and sufficient for NKG2D ligand down-
modulation
The above data clearly demonstrated that UL16 expres-
sion is necessary for HCMV-mediated down-regulation of
NKG2D ligands, but they did not address whether UL16
produced this effect on its own or in association with oth-
er viral products. In order to investigate whether expres-
sion of UL16, outside of the context of the rest of the
HCMV genome, would reproduce the phenotype of the
modified ∆UL16 virus, a transfectant cell line expressing
the MICB molecule, a known ligand of both NKG2D and
UL16, was generated and infected with a panel of vaccinia
viruses including a recombinant vaccinia expressing
UL16. Since cells infected with vaccinia virus become
highly susceptible to NK cell attack, an effect which does
not depend on interactions involving the upregulation of
MIC proteins (S. Chisholm and HTR, unpublished obser-
vations), it was not possible to test the infected transfect-
ant in cytotoxicity assays. Instead, cell surface expression
of MICB, after overnight vaccinia infection, was tested by
flow cytometry (Figure 4). Infection with vaccinia UL16,
but not vaccinia WR or a recombinant vaccinia expressing
ICP-47, led to an almost complete loss of cell surface ex-
pression of MICB, complementing and confirming the
data obtained by study of the UL16 knockout HCMV.
Thus UL16 is necessary and sufficient for MICB down-reg-
ulation. Further, these data strongly argue that the pheno-
type of ∆UL16 depends on the deletion of the UL16 gene
and not on some adventitious mutation selected for dur-
ing the construction of the recombinant virus.
In order to eliminate the possibility that the phenotype of
the knockout virus depended on an effect of inactivation
of the UL16 gene on the transcription of flanking genes,
we studied the expression of UL18 protein in the knock
out virus, as the UL18 gene is located adjacent to UL16
[26]. Lysates of cells infected with AD169 and ∆UL16
were prepared and the expression of the UL18 gene
product was analysed by western blot assay. Fibroblasts
infected with both strains of virus (wild type and knock
out) produced similar amounts of UL18 protein (data not
shown).
Conclusions
The data presented in this paper demonstrate that HCMV
has acquired during its evolution the ability to evade NK
cell immune surveillance and that this ability depends, in
large part, on expression of the viral glycoprotein UL16,
which affects the surface expression of NKG2D ligands.
We could demonstrate that one of these ligands, MICB, is
almost completely lost from the cell surface when the
UL16 gene product is present. MICB is a surface protein,
whose expression is upregulated under conditions of cell
stress [27], and that can activate NK cells through binding
of NKG2D. UL16, by modulating cell surface expression
of molecules like MICB, could be therefore helping
HCMV to evade immune recognition of the infected cell
by disabling a stress-induced signalling pathway.Page 7 of 11
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gp40 (the protein product of the m152 gene), which acts
to inhibit target cell expression of ligands for the NKG2D
receptor [28]. The fact that both HCMV and MCMV, virus-
es that have been evolving independently for more than
20 million years, have acquired during their evolution a
mechanism to interfere with immune surveillance de-
pendent on NKG2D mediated signalling argues that NK
Figure 4
The expression of UL16 is sufficient to affect the surface expression of MICB, an NKG2D ligand. CV1-MICB cells 
(see methods), either uninfected (A) or infected with vaccinia WR (B), vaccinia UL16 (C) or vaccinia ICP47 (D). Cells were 
stained with either human Ig (solid line) or NKG2D-Ig protein (filled histogram) and analysed by flow cytometry. Surface 
expression of MICB is lost in the presence of UL16.
A. Uninfected C. Vaccinia UL16
B. Vaccinia WR D. Vaccinia ICP47Page 8 of 11
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cytomegaloviruses. However, it is important to note that
although HCMV UL16 and MCMV gp40 appear to have
analogous functions they are structurally entirely
unrelated, and thus, it is likely that the mechanisms by
which they interfere with NKG2D ligand expression will
be distinct.
Plausible hypotheses for the mechanism by which the
UL16 protein interferes with the expression of NKG2D lig-
ands include intracellular association of the viral protein
with its cellular targets with either subsequent retention or
destruction of the NKG2D ligand molecules. Alternative-
ly, UL16 might associate with the ligands for NKG2D at
the cell surface. Here it could passively block the binding
of the NKG2D receptor, or it could promote the removal
of these molecules from the cell surface either by internal-
isation or shedding of the NKG2D ligands. At present
there is no real reason to favour any one of these possibil-
ities over the others although it has been reported that
UL16 can be expressed at the cell surface [11].
In summary, these data provide confirmation of the pro-
posed in vivo function of the UL16 protein [11]. This pro-
vides an important clue as to the evolutionary significance
of this protein, but it is possible that UL16 has additional
functions important in modulating the sensitivity of the
target cell to NK cell attack.
Methods
Cells and antibodies
The human foreskin fibroblast cell lines (HFFs) Hs27
(HLA-Cw7 homozygous, ie. inhibited by NK2 effectors)
and HFFF2 (HLACw2, -Cw4, ie. inhibited by NK1 effec-
tors) were obtained from the ECACC and maintained in
DMEM/10% FCS. NK cell lines were prepared from
healthy adult donors as previously described [29]. NK
clones were generated by limiting dilution culture as de-
scribed previously [30]. The KIR phenotype of some of
these NK cell lines and clones was analysed by FACS stain-
ing and in redirected lysis experiments, using the mono-
clonal antibodies EB6 and GL183 (Serotec, Kidlington,
Oxford). For example, clones in Table 1 were as follows:
A5 KIR1- KIR2-, A8 KIR2+, C6 KAR2+, D6 KIR1- KIR2-, D9
KIR1+ KIR2+, F10 KIR1+.
CV1 cells were transfected with a MICB cDNA [31] (a kind
gift of Dr. S. Bahram, INSERM-CreS, Strasbourg, France)
inserted as an Eco RI fragment into the vector pBJNeo
[32]. Populations of cells expressing MICB were FACS
sorted and maintained in DME, 10% FCS with 1 mg/ml
G418.
Anti-HLA class I antibody, HP-1F7 [33], was a gift from
Dr. M. López-Botet (Universitat Pompeu Fabra, CEXS,
Barcelona, Spain). Antibody to CD58 was purchased from
BD Pharmingen. Isotype control mouse monoclonal anti-
bodies were purchased from Sigma. The purified human
IgG1 used as a negative control for the NKG2D-Ig staining
was purchased from Serotec.
Viruses
The Human Cytomegalovirus (HCMV) strains used in
these experiments were AD169 and a recombinant deriv-
ative in which the UL16 sequence was disrupted by a lacZ
expression cassette [17]. Stocks of these viruses were pre-
pared and titred on MRC5 cells. For infection of HFFs an
MOI of 5 was used and a 95–100% cytopathic effect, as
determined by microscopic inspection, was observed by
day 2 post infection.
Recombinant vaccinia viruses expressing UL16 [17] and
ICP-47 [34] (a kind gift of Prof. B.T. Rouse, Dept. of
Microbiology, University of Tenessee) have already been
described. Vaccinia strain WR [35] was a gift from Dr. A.
Alcami (Dept. of Medicine, University of Cambridge).
Vaccinia viruses were propagated and titred in BS-C-1
cells. For the FACS experiments, CV1-MICB transfectants
were infected with the various vaccinia viruses at an MOI
of 10 and analysed for cell surface expression of MICB 12–
16 hrs post-infection.
Production of recombinant NKG2D-Ig
The NKG2D-Ig fusion protein contains the extracellular
portion of the NKG2D molecule fused, in frame, to the
COOH terminus of an N-terminally truncated human
IgG1 heavy chain gene [36] subcloned into the mammali-
an expression vector pcDNA3 (Invitrogen). The sequence
of the oligonucleotides used to amplify NKG2D were 5'-
CGGGATCCAACTCATTATTCAACCAAGAAGTTC-3' and
5'-GCGTGTCGACTACACAGTCCTTTGCTGCAG-3'.
Recombinant protein was produced by transient transfec-
tion of 293T cells and purified from the supernatant by af-
finity chromatography on Protein-G sepharose
(Amersham Pharmacia). Integrity of the purified protein
was checked by SDS-PAGE analysis.
Flow Cytometry
For flow cytometry, 105 cells were preincubated in PBS
containing 1% bovine serum albumin (BSA), 0.1% sodi-
um azide (Sigma) and either 10% normal rabbit serum
(NRS), for staining with NKG2D-Ig or 10% human serum,
for staining with the various mouse mAbs. Cells were
stained with 50 µg/ml of NKG2D-Ig protein followed,
after washing, by phycoerythrin labelled F(ab')2 frag-
ments of goat anti-human Ig (Coulter). Staining with
mouse mAbs was visualised with phycoerythrin labelled
F(ab')2 fragments of goat anti-mouse Ig (Dako). SamplesPage 9 of 11
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Western Blot
Infected HFFs were lysed in 0.5 ml of lysis buffer (50 mM
Tris, 150 mM NaCl, pH 7.5, 1% NP-40 with protease in-
hibitors (Leupeptin and Pepstatin A) and centrifuged to
pellet nuclei. Lysates were resolved by SDS-PAGE on 12%
gels and transferred to Hybond P (Amersham Pharmacia).
Western blots were performed using 10C7 anti-UL18
mAb [37], followed by horseradish peroxidase-conjugat-
ed second antibodies (Dako). Blots were visualised using
the ECL Plus system (Amersham Pharmacia).
Cytotoxicity Assays
The cytolytic activity of NK lines and clones against virus-
infected and uninfected target cell lines was assessed in 4-
h 51Cr release assays. In these assays, 5 × 103 target cell
HFFs were plated in flat-bottomed 96-well microtitre
plates at 37°C, allowed to adhere, and then infected with
either HCMV strain AD169 or the UL16 knockout virus.
After adsorption of the virus for 1–2 h at 37°C, the innoc-
ulum was removed and medium containing 10% FCS was
added. Mock-infected targets were prepared in parallel.
Two days after infection effector cells at various
concentrations were added to the infected and mock-in-
fected targets and the assay incubated at 37°C.
Assays were performed in triplicate, and data values dif-
fered by <10% (on average ~5%) of the mean. In all pre-
sented cytotoxicity assays, the spontaneous release of 51Cr
was <25% (on average ~10%) of the maximal release. All
cytotoxicity assays were performed 6–8 days after restim-
ulation of the NK cells.
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